Accessibility Menu
 

Actuate Therapeutics

(NASDAQ) ACTU

Current Price$2.16
Market Cap$52.76M
Since IPO (2024)-75%
5 YearN/A
1 Year-72%
1 Month-47%

Actuate Therapeutics Financials at a Glance

Market Cap

$52.76M

Revenue (TTM)

$0.00

Net Income (TTM)

$24.12M

EPS (TTM)

$-1.21

P/E Ratio

-1.88

Dividend

$0.00

Beta (Volatility)

0.96 (Low)

Price

$2.16

Volume

591

Open

$2.08

Previous Close

$2.16

Daily Range

$2.08 - $2.23

52-Week Range

$2.05 - $11.99

ACTU News

No articles available.

ACTU: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Actuate Therapeutics

Industry

Biotechnology

Employees

12

CEO

Daniel M. Schmitt, MBA

Headquarters

Fort Worth, TX 76107, US

ACTU Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-296%

Return on Capital

-3%

Return on Assets

-2%

Earnings Yield

-53.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$52.76M

Shares Outstanding

23.24M

Volume

591

Short Interest

0.00%

Avg. Volume

73.51K

Financials (TTM)

Gross Profit

$0.00

Operating Income

$22.50M

EBITDA

$22.50M

Operating Cash Flow

$19.21M

Capital Expenditure

$0.00

Free Cash Flow

$19.21M

Cash & ST Invst.

$13.16M

Total Debt

$0.00

Actuate Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$52.76M

N/A

Market Cap/Employee

$5.28M

N/A

Employees

10

N/A

Net Income

$5.41M

+9.4%

EBITDA

$5.40M

+9.5%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Net Cash

$13.16M

+52.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-1.72%

N/A

Return on Invested Capital

-2.93%

N/A

Free Cash Flow

$3.74M

+21.7%

Operating Cash Flow

$3.74M

+21.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MCRBSeres Therapeutics, Inc.
$9.00-3.54%
VTGNVistaGen Therapeutics, Inc.
$0.57-5.87%
APLTApplied Therapeutics, Inc.
$0.10+0.00%
VORVor Biopharma Inc.
$14.48+6.71%

Trending Stocks

Symbol / CompanyPricePrice Chg
TQQQProShares Trust - ProShares UltraPro Qqq
$38.78-0.06%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.28+0.05%
QQQInvesco QQQ Trust
$562.58-0.02%
ARTLArtelo Biosciences
$10.54+2.30%

Questions About ACTU

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.